Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 2
1949 5
1950 3
1951 6
1952 6
1953 8
1954 6
1955 7
1956 4
1957 7
1958 3
1959 4
1960 2
1961 8
1962 6
1963 4
1964 2
1975 10
1976 19
1977 17
1978 17
1979 23
1980 21
1981 38
1982 98
1983 78
1984 127
1985 192
1986 250
1987 271
1988 290
1989 431
1990 501
1991 572
1992 619
1993 713
1994 749
1995 809
1996 865
1997 853
1998 867
1999 870
2000 915
2001 935
2002 876
2003 822
2004 838
2005 862
2006 913
2007 865
2008 817
2009 804
2010 870
2011 879
2012 923
2013 863
2014 912
2015 937
2016 907
2017 859
2018 817
2019 829
2020 983
2021 982
2022 884
2023 813
2024 297

Text availability

Article attribute

Article type

Publication date

Search Results

28,592 results

Results by year

Filters applied: . Clear all
Page 1
Differential Effect of 4H-Benzo[d] [1, 3]oxazines on the Proliferation of Breast Cancer Cell Lines.
Fraire-Soto I, Araujo-Huitrado JG, Granados-López AJ, Segura-Quezada LA, Ortiz-Alvarado R, Herrera MD, Gutiérrez-Hernández R, Reyes-Hernández CA, López-Hernández Y, Tapia-Juárez M, Negrete-Díaz JV, Chacón-García L, Solorio-Alvarado CR, López JA. Fraire-Soto I, et al. Curr Med Chem. 2024 Apr 26. doi: 10.2174/0109298673292365240422104456. Online ahead of print. Curr Med Chem. 2024. PMID: 38676529
METHOD: The precursors and oxazines obtained were studied in breast cancer cell lines MCF-7, CAMA-1, HCC1954 and SKBR-3 with differential biological activity showing various degrees of inhibition with a notable effect for those that had an aryl substituted at C-2 of the molecules …
METHOD: The precursors and oxazines obtained were studied in breast cancer cell lines MCF-7, CAMA-1, HCC1954 and SKBR-3 with differential bi …
Anthriscus sylvestris-Noxious Weed or Sustainable Source of Bioactive Lignans?
Berežni S, Mimica-Dukić N, Domina G, Raimondo FM, Orčić D. Berežni S, et al. Plants (Basel). 2024 Apr 12;13(8):1087. doi: 10.3390/plants13081087. Plants (Basel). 2024. PMID: 38674496 Review.
One of the main compounds of A. sylvestris, deoxypodophyllotoxin, among its wide-ranging effects, including antitumor, antiproliferative, antiplatelet aggregation, antiviral, anti-inflammatory, and insecticidal properties, serves as a pivotal precursor to epipodophyllotoxin, cruc …
One of the main compounds of A. sylvestris, deoxypodophyllotoxin, among its wide-ranging effects, including antitumor, antiproliferative, an …
Role of Protein Tyrosine Phosphatase Receptor Type E (PTPRE) in Chemoresistant Retinoblastoma.
Mohren L, Doege A, Miroschnikov N, Dräger O, Busch MA, Dünker N. Mohren L, et al. Int J Mol Sci. 2024 Apr 22;25(8):4572. doi: 10.3390/ijms25084572. Int J Mol Sci. 2024. PMID: 38674157
Lentiviral PTPRE knockdown (KD) induced a significant decrease in growth kinetics, cell viability, and anchorage-independent growth of etoposide-resistant Y79 and WERI RB cells. Caspase-dependent apoptosis rates were significantly increased and a re-sensitization for et …
Lentiviral PTPRE knockdown (KD) induced a significant decrease in growth kinetics, cell viability, and anchorage-independent growth of et …
Evaluation of Stages, Treatment Protocols, and Outcomes of Colorectal Cancer among West Bank Patients.
Sawaid IO, Samson AO, Al-Ramahi R. Sawaid IO, et al. J Clin Med. 2024 Apr 15;13(8):2284. doi: 10.3390/jcm13082284. J Clin Med. 2024. PMID: 38673557
., folinic acid, fluorouracil, irinotecan), while the 187 remaining patients (74.2%) were treated with capecitabine, oxaliplatin, bevacizumab, cetuximab, regorafenib, cisplatin, etoposide, gemcitabine, or a combination thereof. The sample was categorized into six outcomes: …
., folinic acid, fluorouracil, irinotecan), while the 187 remaining patients (74.2%) were treated with capecitabine, oxaliplatin, bevacizuma …
A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.
Tang FF, Duan WB, Liu XH, Lu SY, Zhao XS, Qin YZ, Jia JS, Wang J, Gong LZ, Jiang Q, Zhao T, Shi HX, Chang YJ, Huang XJ, Jiang H. Tang FF, et al. Br J Haematol. 2024 Apr 26. doi: 10.1111/bjh.19464. Online ahead of print. Br J Haematol. 2024. PMID: 38671583
For induction therapy (IT), in addition to all-trans retinoic acid (ATRA) and oral arsenic (RIF), 22 patients received oral etoposide (VP16) as cytotoxic chemotherapy (CC), and 38 patients received intravenous CC as historical control group. ...
For induction therapy (IT), in addition to all-trans retinoic acid (ATRA) and oral arsenic (RIF), 22 patients received oral etoposide …
Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer.
Huang S, Sheng G, Lv Q, Li Y, Meng Q, Gao X, Shang Z. Huang S, et al. J Gynecol Oncol. 2024 Apr 22. doi: 10.3802/jgo.2024.35.e100. Online ahead of print. J Gynecol Oncol. 2024. PMID: 38670563
This retrospective study aimed to assess the efficacy and safety of combined anlotinib-oral etoposide treatment for patients with PROC. METHODS: Data of 23 patients who were diagnosed with PROC from January 2020 to November 2022 and treated with anlotinib combined with ora …
This retrospective study aimed to assess the efficacy and safety of combined anlotinib-oral etoposide treatment for patients with PRO …
TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy.
Nguyen T, Carrieri FA, Connis N, Lafargue A, Chang J, Chan A, Shetty AC, Song Y, Hoang T, Jagtap S, Chowdhury DD, Khan MA, Gabrielson KL, Rezaee M, Torres-Ayuso P, Brognard J, Hann CL, Tran PT. Nguyen T, et al. Mol Cancer Ther. 2024 Apr 27. doi: 10.1158/1535-7163.MCT-23-0412. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38670554
Employing a range of human LSCC cell lines and the TNIK inhibitor NCB-0846, we investigated the potential of TNIK as a chemo- and radiosensitizing target with in vitro and in vivo preclinical models. The combination of NCB-0846 with cisplatin or etoposide was at best addit …
Employing a range of human LSCC cell lines and the TNIK inhibitor NCB-0846, we investigated the potential of TNIK as a chemo- and radiosensi …
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.
Shi H, Yang F, Cao M, Xu T, Zheng P, Guo Y, Su G, Feng S, Li R, Liu R, Liu H, Ma L, Ke X, Hu K. Shi H, et al. Ann Hematol. 2024 Apr 25. doi: 10.1007/s00277-024-05775-z. Online ahead of print. Ann Hematol. 2024. PMID: 38662205
In light of these findings, we conducted a safety and efficacy evaluation of the enhanced treatment regimen, combining Dara and Ven with aclarubicin, cytarabine, granulocyte colony-stimulating factor, and etoposide (CAGE), in patients suffering from R/R T-ALL/LBL. The part …
In light of these findings, we conducted a safety and efficacy evaluation of the enhanced treatment regimen, combining Dara and Ven with acl …
Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.
Yu TT, Hu X, Liufu WJ, Niu SQ, Lian HM, Ma HL, Wang J, Bao Y, Chen M, Peng F. Yu TT, et al. Cancer Med. 2024 Apr;13(8):e7215. doi: 10.1002/cam4.7215. Cancer Med. 2024. PMID: 38659392 Free PMC article. Clinical Trial.
OBJECTIVES: The recommended treatment for limited-stage small-cell lung cancer (LS-SCLC) is a combination of thoracic radiotherapy (TRT) and etoposide plus cisplatin (EP) chemotherapy, typically administered over 4-6 cycles. ...
OBJECTIVES: The recommended treatment for limited-stage small-cell lung cancer (LS-SCLC) is a combination of thoracic radiotherapy (TRT) and …
28,592 results
You have reached the last available page of results. Please see the User Guide for more information.